The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Drug-Induced Parkinsonism
Open accessAbstract
Drug-induced parkinsonism (DIP) is the second-most-common etiology of parkinsonism in the elderly after Parkinson's disease (PD). Many patients with DIP may be misdiagnosed with PD because the clinical features of these two conditions are indistinguishable. Moreover, neurological deficits in patients with DIP may be severe enough to affect daily activities and may persist for long periods of time after the cessation of drug taking. In addition to typical antipsychotics, DIP may be caused by gastrointestinal prokinetics, calcium channel blockers, atypical antipsychotics, and antiepileptic drugs. The clinical manifestations of DIP are classically described as bilateral and symmetric parkinsonism without tremor at rest. However, about half of DIP patients show asymmetrical parkinsonism and tremor at rest, making it difficult to differentiate DIP from PD. The pathophysiology of DIP is related to drug-induced changes in the basal ganglia motor circuit secondary to dopaminergic receptor blockade. Since these effects are limited to postsynaptic dopaminergic receptors, it is expected that presynaptic dopaminergic neurons in the striatum will be intact. Dopamine transporter (DAT) imaging is useful for diagnosing presynaptic parkinsonism. DAT uptake in the striatum is significantly decreased even in the early stage of PD, and this characteristic may help in differentiating PD from DIP. DIP may have a significant and longstanding effect on patients' daily lives, and so physicians should be cautious when prescribing dopaminergic receptor blockers and should monitor patients' neurological signs, especially for parkinsonism and other movement disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,419
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Van Gompel, P., Lesage, A. S., De Loore, K., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
(1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401003 · Cited by 615
Dopamine receptors and brain function
Jaber, M., Robinson, S. W., Missale, C., & Caron, M. G. (1996) · Neuropharmacology · doi:10.1016/s0028-3908(96)00100-1 · Cited by 570
Effects of Newer Antipsychotics on Extrapyramidal Function
Tarsy, D., Baldessarini, R. J., & Tarazi, F. I. (2002) · CNS Drugs · doi:10.2165/00023210-200216010-00003 · Cited by 313
The role of DAT-SPECT in movement disorders
Kagi, G., Bhatia, K. P., & Tolosa, E. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.157370 · Cited by 311
Wenning, G. K., Kiechl, S., Seppi, K., Müller, J., Högl, B., Saletu, M., Rungger, G., Gasperi, A., Willeit, J., & Poewe, W. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70226-x · Cited by 302
Tonini, M., Cipollina, L., Poluzzi, E., Crema, F., Corazza, G. R., & De Ponti, F. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01867.x · Cited by 291
Barbosa, M. T., Caramelli, P., Maia, D. P., Cunningham, M. C. Q., Guerra, H. L., Lima‐Costa, M. F., & Cardoso, F. (2006) · Movement Disorders · doi:10.1002/mds.20806 · Cited by 284
Dopamine transporters decrease with age.
Volkow, N. D., Ding, Y., Fowler, J. S., Wang, G., Logan, J., Gatley, S. J., Hitzemann, R., Smith, G., Fields, S. D., & Gur, R. C. (1996) · PubMed · Cited by 262
Rabey, J. M., Prokhorov, T., Miniovitz, A., Dobronevsky, E., & Klein, C. (2007) · Movement Disorders · doi:10.1002/mds.21116 · Cited by 259
Markers of Glutamatergic Neurotransmission and Oxidative Stress Associated With Tardive Dyskinesia
Tsai, G., Goff, D. C., Chang, R. W., Flood, J., Baer, L., & Coyle, J. T. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.9.1207 · Cited by 243
Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain
Benito‐León, J., Bermejo‐Pareja, F., Rodríguez, J., Molina, J., Gabriel, R., Morales, J., & for the Neurological Disorders in Central Spain (NEDICES) Study Group (2003) · Movement Disorders · doi:10.1002/mds.10362 · Cited by 233
Role of DAT‐SPECT in the diagnostic work up of Parkinsonism
Scherfler, C., Schwarz, J., Antonini, A., Grosset, D., Valldeoriola, F., Marek, K., Oertel, W., Tolosa, E., Lees, A. J., & Poewe, W. (2007) · Movement Disorders · doi:10.1002/mds.21505 · Cited by 219
ŒSTROGENS AND EXTRAPYRAMIDAL SYSTEM
Bedard, P., Langelier, P., & Villeneuve, A. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90429-9 · Cited by 179
DRUG-INDUCED PARKINSONISM IN THE ELDERLY
Stephen, P., & Williamson, J. (1984) · The Lancet · doi:10.1016/s0140-6736(84)91516-2 · Cited by 178
Metoclopramide-induced movement disorders. Clinical findings with a review of the literature
Miller, L. G. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.149.11.2486 · Cited by 177
Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa.
Hardie, R. J., & Lees, A. J. (1988) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.850 · Cited by 155
[123I]‐FP/CIT SPECT imaging for distinguishing drug‐induced parkinsonism from Parkinson's disease
Lorberboym, M., Treves, T. A., Melamed, E., Lampl, Y., Hellmann, M. A., & Djaldetti, R. (2005) · Movement Disorders · doi:10.1002/mds.20748 · Cited by 154
Drug induced parkinsonism: a common cause of parkinsonism in older people
Thanvi, B., & Treadwell, S. D. (2009) · Postgraduate Medical Journal · doi:10.1136/pgmj.2008.073312 · Cited by 154
Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients.
Janno, S., Holi, M., Tuisku, K., & Wahlbeck, K. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.160 · Cited by 152
KUROKI, T., NAGAO, N., & NAKAHARA, T. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00910-2 · Cited by 146
Reversible Drug-Induced Parkinsonism
Rajput, A. H. (1982) · Archives of Neurology · doi:10.1001/archneur.1982.00510220042009 · Cited by 145
Metoclopramide-Induced Movement Disorders
Miller, L. G. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390110070015 · Cited by 139
Drug‐induced parkinsonism: a review
Montastruc, J., Llau, M. E., Rascol, O., & Sénard, J. (1994) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.1994.tb00808.x · Cited by 135
Quetiapine improves psychotic symptoms and cognition in Parkinson's disease
Juncos, J. L., Roberts, V. J., Evatt, M. L., Jewart, R. D., Wood, C. D., Potter, L. S., Jou, H.-C., & Yeung, P. P. (2004) · Movement Disorders · doi:10.1002/mds.10620 · Cited by 126
DAT imaging in drug-induced and psychogenic parkinsonism
TOLOSA, E. S., Coelho, M. M., & Gallardo, M. (2003) · Movement Disorders · doi:10.1002/mds.10575 · Cited by 104
Failure of recognition of drug‐induced parkinsonism in the elderly
Esper, C. D., & Factor, S. A. (2007) · Movement Disorders · doi:10.1002/mds.21854 · Cited by 98
Inada, T., Koga, M., Ishiguro, H., Horiuchi, Y., Syu, A., Yoshio, T., Takahashi, N., Ozaki, N., & Arinami, T. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f70492 · Cited by 97
Molecular Imaging of the Dopamine Transporter
Varrone, A., & Halldin, C. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.065656 · Cited by 96
A Placebo-Controlled, Double-Blind, Cross-Over Trial of Flunarizine in Common Migraine
Sørensen, P. S., Hansen, K., & Olesen, J. (1986) · Cephalalgia · doi:10.1046/j.1468-2982.1986.0601007.x · Cited by 94
Neuroleptic drug exposure and treatment of parkinsonism in the elderly: A case-control study
Avorn, J., Bohn, R. L., Mogun, H., Gurwitz, J. H., Monane, M., Everitt, D. E., & Walker, A. M. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80104-1 · Cited by 91
Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT
Lavalaye, J., LINSZEN, D. H., Booij, J., Dingemans, P. M. A. J., Reneman, L., Habraken, J. B. A., Gersons, B. P. R., & van Royen, E. A. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00023-2 · Cited by 88
Metoclopramide, an Increasingly Recognized Cause of Tardive Dyskinesia
Kenney, C., Hunter, C., Davidson, A. L., & Jankovic, J. J. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007312258 · Cited by 86
An Animal Model for Coexisting Tardive Dyskinesia and Tardive Parkinsonism
Gunne, L. M., & Andrén, P. E. (1993) · Clinical Neuropharmacology · doi:10.1097/00002826-199302000-00012 · Cited by 76
The Safety of Olanzapine Compared With Other Antipsychotic Drugs
Gómez, J. C., Sacristán, J. A., Hernández‐Rivas, J. M., Breier, A. F., Carrasco, P. R., Sáiz, C. A., Carbonell, E. F., & the EFESO Study Group (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0503 · Cited by 72
Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson’s disease
Diaz-Corrales, F. J. J., Viedma, S. S., García-Solís, D., Escobar-Delgado, T., & Mir, P. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1289-4 · Cited by 64
Susatia, F., & Fernandez, H. H. (2009) · Current Treatment Options in Neurology · doi:10.1007/s11940-009-0019-3 · Cited by 61
Poewe, W. H., & Scherfler, C. (2003) · Movement Disorders · doi:10.1002/mds.10573 · Cited by 60
Neuronal basis of neuroleptic-induced extrapyramidal side effects.
Ossowska, K. (2002) · PubMed · Cited by 48
Drug-induced parkinsonism in a movement disorders unit: A four-year survey
Jiménez-Jiménez, F. J., Pareja, M. O., Ayuso‐Peralta, L., Gasalla, T., Cabrera‐Valdivia, F., Vaquero, A., Tejeiro, J., & García-Albea, E. (1996) · Parkinsonism & Related Disorders · doi:10.1016/1353-8020(96)00013-2 · Cited by 45
Aripiprazole associated with severe exacerbation of Parkinson's disease
Wickremaratchi, M. M., Morris, H. R., & Ali, I. M. (2006) · Movement Disorders · doi:10.1002/mds.21025 · Cited by 41
Aripiprazole-induced parkinsonism
Sharma, A., & Sorrell, J. H. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000185025.40656.30 · Cited by 33
Liou, Y., Wang, Y., Chen, J.-Y., Bai, Y., Lin, C.-C., Liao, D., Chen, T.-T., Chen, M., Mo, G., & Lai, I. (2007) · Psychiatry Research · doi:10.1016/j.psychres.2006.08.007 · Cited by 29
Disabling Parkinsonism Due to Lithium: A Case Report
Holroyd, S., & Smith, D. (1995) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879500800208 · Cited by 27
Melaine Johns Cupp, Toxicology and Clinical Pharmacology of Herbal Products
Sarker, S. D. (2002) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357021778358 · Cited by 15
Stahl, S. M. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1001 · Cited by 14
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
The anatomy and physiology of normal and abnormal swallowing in oropharyngeal dysphagia
Sasegbon, A., & Hamdy, S. (2017) · Neurogastroenterology & Motility · doi:10.1111/nmo.13100 · Cited by 287
Metadata
- Authors
- Shin, H.-W., & Chung, S. J.
- Venue
- Journal of Clinical Neurology
- Publisher
- Korean Neurological Association
- Published
- 2012
- Volume
- 8
- Issue
- 1
- Pages
- 15
- ISSN
- 1738-6586 (ISSN-L)
- 2005-5013
- OpenAlex
- W2110767684
- Cited by
- 354
- References
- 48
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.